Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | AGXT | P21549 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2386075 | 1.00 | TSHR (0.61) | TSHRTAAR1LMNASLC6A2HTR1A | |
| SCHEMBL9679098 | 1.00 | TSHR (0.61) | TSHRTAAR1LMNASLC6A2HTR1A | |
| SCHEMBL13941992 | 1.00 | TSHR (0.61) | TSHRTAAR1LMNASLC6A2HTR1A | |
| SCHEMBL24215035 | 1.00 | TSHR (0.61) | TSHRTAAR1LMNASLC6A2HTR1A | |
| SCHEMBL4140966 | 0.90 | SLC6A2 (0.53) | TSHRTAAR1LMNASLC6A2HTR1A | |
| SCHEMBL4140963 | 0.90 | SLC6A2 (0.53) | TSHRTAAR1LMNASLC6A2HTR1A | |
| SCHEMBL8662256 | 0.90 | SLC6A2 (0.53) | TSHRTAAR1LMNASLC6A2HTR1A | |
| SCHEMBL7349197 | 0.90 | SLC6A2 (0.53) | TSHRTAAR1LMNASLC6A2HTR1A | |
| SCHEMBL7344189 | 0.90 | SLC6A2 (0.53) | TSHRTAAR1LMNASLC6A2HTR1A | |
| SCHEMBL4140962 | 0.90 | SLC6A2 (0.53) | TSHRTAAR1LMNASLC6A2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220204433-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF ELDECALCITOL | FAES FARMA, S.A. (ES) | 2022-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204433-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF ELDECALCITOL | CYP24A1, CYP2R1, PTH1R | TSHR 1961/4885TAAR1 4736/4885LMNA 988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.